Literature DB >> 33900517

Epigenetic Modulation in Parkinson's Disease and Potential Treatment Therapies.

Aaina Singh Rathore1, Hareram Birla1, Saumitra Sen Singh1, Walia Zahra1, Hagera Dilnashin1, Richa Singh1, Priyanka Kumari Keshri1, Surya Pratap Singh2.   

Abstract

In the recent past, huge emphasis has been given to the epigenetic alterations of the genes responsible for the cause of neurological disorders. Earlier, the scientists believed somatic changes and modifications in the genetic makeup of DNA to be the main cause of the neurodegenerative diseases. With the increase in understanding of the neural network and associated diseases, it was observed that alterations in the gene expression were not always originated by the change in the genetic sequence. For this reason, extensive research has been conducted to understand the role of epigenetics in the pathophysiology of several neurological disorders including Alzheimer's disease, Parkinson's disease and, Huntington's disease. In a healthy person, the epigenetic modifications play a crucial role in maintaining the homeostasis of a cell by either up-regulating or down-regulating the genes. Therefore, improved understanding of these modifications may provide better insight about the diseases and may serve as potential therapeutic targets for their treatment. The present review describes various epigenetic modifications involved in the pathology of Parkinson's Disease (PD) backed by multiple researches carried out to study the gene expression regulation related to the epigenetic alterations. Additionally, we will briefly go through the current scenario about the various treatment therapies including small molecules and multiple phytochemicals potent enough to reverse these alterations and the future directions for a better management of PD.

Entities:  

Keywords:  Acetylation; Deacetylation; Epigenetic modulators; Methylation; Parkinson’s disease; RNA based gene regulation

Year:  2021        PMID: 33900517     DOI: 10.1007/s11064-021-03334-w

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  35 in total

1.  Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains.

Authors:  Ahmad Jowaed; Ina Schmitt; Oliver Kaut; Ullrich Wüllner
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

Review 2.  Epigenetic modifications and human disease.

Authors:  Anna Portela; Manel Esteller
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

Review 3.  The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Fumiaki Mori; Hitoshi Takahashi
Journal:  Neuropathology       Date:  2007-10       Impact factor: 1.906

Review 4.  Epigenetic regulation in Parkinson's disease.

Authors:  Catherine Labbé; Oswaldo Lorenzo-Betancor; Owen A Ross
Journal:  Acta Neuropathol       Date:  2016-06-29       Impact factor: 17.088

5.  The heritability of risk and age at onset of Parkinson's disease after accounting for known genetic risk factors.

Authors:  Taye H Hamza; Haydeh Payami
Journal:  J Hum Genet       Date:  2010-03-05       Impact factor: 3.172

6.  Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes.

Authors:  Eliezer Masliah; Wilmar Dumaop; Douglas Galasko; Paula Desplats
Journal:  Epigenetics       Date:  2013-08-01       Impact factor: 4.528

7.  Lewy bodies.

Authors:  Clifford W Shults
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-31       Impact factor: 11.205

8.  CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease.

Authors:  Lumine Matsumoto; Hiroshi Takuma; Akira Tamaoka; Hiroshi Kurisaki; Hidetoshi Date; Shoji Tsuji; Atsushi Iwata
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

9.  Methylation status and neurodegenerative markers in Parkinson disease.

Authors:  Rima Obeid; Achim Schadt; Ulrich Dillmann; Panagiotis Kostopoulos; Klaus Fassbender; Wolfgang Herrmann
Journal:  Clin Chem       Date:  2009-08-13       Impact factor: 8.327

10.  Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease.

Authors:  Margaux F Keller; Mohamad Saad; Jose Bras; Francesco Bettella; Nayia Nicolaou; Javier Simón-Sánchez; Florian Mittag; Finja Büchel; Manu Sharma; J Raphael Gibbs; Claudia Schulte; Valentina Moskvina; Alexandra Durr; Peter Holmans; Laura L Kilarski; Rita Guerreiro; Dena G Hernandez; Alexis Brice; Pauli Ylikotila; Hreinn Stefánsson; Kari Majamaa; Huw R Morris; Nigel Williams; Thomas Gasser; Peter Heutink; Nicholas W Wood; John Hardy; Maria Martinez; Andrew B Singleton; Michael A Nalls
Journal:  Hum Mol Genet       Date:  2012-08-13       Impact factor: 6.150

View more
  5 in total

Review 1.  The role of histone modifications: from neurodevelopment to neurodiseases.

Authors:  Jisu Park; Kyubin Lee; Kyunghwan Kim; Sun-Ju Yi
Journal:  Signal Transduct Target Ther       Date:  2022-07-06

2.  The Potential Circular RNAs Biomarker Panel and Regulatory Networks of Parkinson's Disease.

Authors:  Yousheng Xiao; Hongchang Chen; Jiajia Liao; Qinxin Zhang; Honghu He; Jiang Lei; Jinjun Huang; Qiang Ouyang; Yuefei Shen; Jin Wang
Journal:  Front Neurosci       Date:  2022-05-13       Impact factor: 5.152

3.  The understanding of Parkinson's disease through genetics and new therapies.

Authors:  Olivier Uwishema; Helen Onyeaka; Rawa Badri; Ayşe Nazlı Yücel; Ahmet Kayhan Korkusuz; Abayomi Oyeyemi Ajagbe; Amro Abuleil; Céline Chaaya; Baraa H M Alhendawi; Elie Chalhoub
Journal:  Brain Behav       Date:  2022-04-21       Impact factor: 3.405

4.  Targeting the epigenome to treat neurodegenerative diseases or delay their onset: a perspective.

Authors:  Fabio Coppede
Journal:  Neural Regen Res       Date:  2022-08       Impact factor: 5.135

Review 5.  Emerging Role of Neuron-Glia in Neurological Disorders: At a Glance.

Authors:  Md Mominur Rahman; Md Rezaul Islam; Md Yamin; Md Mohaimenul Islam; Md Taslim Sarker; Atkia Farzana Khan Meem; Aklima Akter; Talha Bin Emran; Simona Cavalu; Rohit Sharma
Journal:  Oxid Med Cell Longev       Date:  2022-08-22       Impact factor: 7.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.